male androgenetic alopecia. Androgenic alopecia
Conditions
Interventions
Intervention 1: In the intervention group, daily finasteride 1 mg tablets manufactured by Soha Pharmaceutical Company will be prescribed for patients, as well as 150 units of botulinum toxin type A Ma
Sponsors
Shiraz University of Medical Sciences
Eligibility
Sex/Gender
Male
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Being male and older than 18 years 2. Suffering from androgenic alopecia grade 3 to 5 based on the Norwood Hamilton classification and Not receiving treatment for androgenic alopecia during the last 3 months
Exclusion criteria
Exclusion criteria: 1. Severe diseases of internal organs, eyes or skin 2. Diseases of the neuromuscular system 3. Inflammation, infection or unhealed wounds on the skin around the injection site on the head 4. Receiving systematic treatment with corticosteroids or other immunosuppressants and immune modulators in the last 3 months 5. Receiving anticoagulant and antiplatelet drugs 6. Hair transplantation in the past 7. Infectious underlying disease, autoimmune, malignancy 8. Phobia about treatment with botulinum toxin 9. Reluctance to continue Study participation during treatment and follow-up
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hair density. Timepoint: Measurement of hair density at the beginning of the study and at the end of month 3 and at the end of month 6. Method of measurement: Photographing with a visioface 1000 D device. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Ladan Dastgheib
Shiraz University of Medical Sciences
Outcome results
None listed